Pharmacy Times hosted a CME-eligible virtual symposium May 19 (1:00-2:30 PM EDT) framing the post-RFK Jr. peptide moment for hospital and retail pharmacists. The agenda crossed the wellness-clinic side (BPC-157, TB-500, CJC-1295, GHK-Cu after the April 22 503A Category-2 removal) with the FDA-approved peptide side (semaglutide, tirzepatide, liraglutide, navepegritide, paltusotine) and walked attendees through the July 23-24 PCAC vote calculus and patient counseling around compounded GLP-1 risk.
Pharmacy Times ran a Ferry Ossendorp Q&A on May 5 walking through the mechanistic case for peptide-based cancer vaccines: T cells recognize small peptides presented on the surface of tumor cells, and synthetic peptides matched to tumor antigens can be used to vaccinate the immune system to recognize and target those tumors. Ossendorp's own work showed that knowledge of a tumor's antigen profile combined with peptide vaccination can protect against very aggressive tumors in animal models. The piece sits inside a 2026 peptide-vaccine pipeline with 31 active personalized cancer-vaccine trials registered (more than dendritic-cell or RNA-vaccine platforms), the BioVaxys MVP-S survivin program heading to ASCO 2026, the Greenwich GP2/GLSI-100 FLAMINGO-01 readout, and the BriaCell Bria-IMT Phase 3.